7-acetyl-2-mercaptobenzoxazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 7-acetyl-2-mercaptobenzoxazole
• 英文别名: 7-acetyl-2-mercaptobenzooxazole；1-(2-sulfanylidene-3H-1,3-benzoxazol-7-yl)ethanone
• 化学式: C₉H₇NO₂S
• 分子量: 193.226
• InChiKey: KDNAQPMVJYHVAJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  70.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  吡唑 、 7-acetyl-2-mercaptobenzoxazole 在 2-碘苯甲酸 、 tetrabutylammonium tetrafluoroborate 、 三氟乙酸 、 sodium chloride 作用下， 以 乙腈 为溶剂， 以70%的产率得到1-(2-(1H-pyrazol-1-yl)benzo[d]oxazol-7-yl)ethan-1-one
  参考文献：
  名称：

  碘催化杂芳硫醇电化学脱硫胺化

  摘要：

  我们报道，2-碘苯甲酸的阳极氧化能够实现杂芳族硫醇脱硫胺化的高价碘（III）电催化。该方案具有广泛的底物范围和广泛的官能团耐受性，以良好至优异的产率提供目标N -杂环胺。

  DOI：

  10.1002/cctc.202301750
• 作为产物：
  描述：

  3-氨基-2-羟基苯乙酮 、 potassium ethyl xanthogenate 在 水 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以to provide 134 mg (yield 92%) of 7-acetyl-2-mercaptobenzooxazole as a dark solid的产率得到7-acetyl-2-mercaptobenzoxazole
  参考文献：
  名称：

  Cyclic diamine compounds and medicine containing the same

  摘要：

  本发明提供了新型的环状二胺化合物和含有该化合物的药物组合物。本发明涉及一种由式（I）表示的化合物或其盐或溶剂（其中，在该式中，Ar为可选取代芳基；X为—NH—、氧原子或硫原子；Y为—NR1—、氧原子、硫原子、亚砜或亚磺酰基；Z为单键或—NR2—；R1为氢原子、可选取代的低碳基、可选取代的芳基或可选取代的硅烷低碳基；R2为氢原子、可选取代的低碳基、可选取代的芳基或可选取代的硅烷低碳基；l为0至15的整数；m为2或3的整数；n为0至3的整数）。本发明的化合物可用作药物组合物，特别是作为酰基辅酶A胆固醇酰基转移酶（ACAT）的抑制剂。

  公开号：

  US06969711B2

文献信息

• Anilide compounds and drugs containing the same
  申请人：Kowa Company, Ltd.

  公开号：US06362208B1

  公开（公告）日：2002-03-26

  The invention relates to a novel anilide compound and a pharmaceutical composition comprising the same. The invention relates to a compound represented by the following general formula: represents a divalent residue of benzene with a substituent(s), heterocycle-condensed benzene which may or may not have a substituent, pyridine which may or may not have a substituent, cyclohexane or naphthalene or Ar represents an aryl group which may or may not have a substituent; X represents —NH—, oxygen atom or sulfur atom; Y represents —NR4—, oxygen atom, sulfur atom, sulfoxide or sulfone; Z represents single bond or —NR5—; R4 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; R5 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; and n represents an integer of 0 to 15. The inventive compounds are useful in the form of pharmaceutical composition, specifically as acyl coenzyme A cholesterol acyltransferase (ACAT) inhibitor.

  该发明涉及一种新型苯胺类化合物和包含该化合物的药物组合物。该发明涉及一种由以下通用式表示的化合物：表示苯的一个带有取代基的二价残基，杂环并联苯可能具有或不具有取代基，吡啶可能具有或不具有取代基，环己烷或萘或Ar代表可能具有或不具有取代基的芳基；X代表—NH—、氧原子或硫原子；Y代表—NR4—、氧原子、硫原子、亚硫醚或砜；Z代表单键或—NR5—；R4代表氢原子、较低烷基、芳基或可能具有或不具有取代基的硅烷化较低烷基；R5代表氢原子、较低烷基、芳基或可能具有或不具有取代基的硅烷化较低烷基；n代表0到15之间的整数。这些创新化合物在药物组合物的形式中非常有用，特别作为酰辅酶A胆固醇酰转移酶（ACAT）抑制剂。
• Novel cyclic diamine compounds and medicine containing the same
  申请人：Kowa Company, Ltd.

  公开号：US20040038987A1

  公开（公告）日：2004-02-26

  The present invention offers novel cyclic diamine compounds and a pharmaceutical composition containing the same. The present invention relates to a compound represented by the formula (I) or salt(s) or solvate(s) thereof. 1 (In the formula, 2 is an optionally substituted divalent residue of benzene, pyridine, cyclohexane or naphthalene or is a vinylene group where Ar is an optionally substituted aryl group; X is —NH—, oxygen atom or sulfur atom; Y is —NR 1 —, oxygen atom, sulfur atom, sulfoxide or sulfone; Z is a single bond or —NR 2 —; R 1 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; R 2 is hydrogen atom, optionally substituted lower alkyl group, optionally substituted aryl group or optionally substituted silyl lower alkyl group; l is an integer of from 0 to 15; m is an integer of 2 or 3; and n is an integer of from 0 to 3). The compound of the present invention is useful as a pharmaceutical composition, particuarly as an inhibitor of acyl coenzyme A cholesterol acyltransferase (ACAT).

  本发明提供了新颖的环状二胺化合物以及含有该化合物的药物组合物。本发明涉及由式(I)表示的化合物或其盐或溶剂化合物。(在该式中，2是苯、吡啶、环己烷或萘的可选择取代的二价残基，或者是Ar为可选择取代芳基的乙烯基；X为—NH—、氧原子或硫原子；Y为—NR1—、氧原子、硫原子、亚砜或砜；Z为单键或—NR2—；R1为氢原子、可选择取代的较低烷基、可选择取代的芳基或可选择取代的硅烷较低烷基；R2为氢原子、可选择取代的较低烷基、可选择取代的芳基或可选择取代的硅烷较低烷基；l为0到15的整数；m为2或3的整数；n为0到3的整数)。本发明的化合物可用作药物组合物，特别是作为酰辅酶A胆固醇酰基转移酶(ACAT)的抑制剂。
• NOVEL ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME
  申请人：Kowa Co., Ltd.

  公开号：EP1020451A1

  公开（公告）日：2000-07-19

  The invention relates to a novel anilide compound and a pharmaceutical composition comprising the same. The invention relates to a compound represented by the following general formula:    represents a divalent residue of benzene with a substituent(s), heterocycle-condensed benzene which may or may not have a substituent, pyridine which may or may not have a substituent, cyclohexane or naphthalene or Ar represents an aryl group which may or may not have a substituent; X represents -NH-, oxygen atom or sulfur atom; Y represents -NR4-, oxygen atom, sulfur atom, sulfoxide or sulfone; Z represents single bond or -NR5-; R4 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; R5 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; and n represents an integer of 0 to 15. The inventive compounds are useful in the form of pharmaceutical composition, specifically as acyl coenzyme A cholesterol acyltransferase (ACAT) inhibitor.

  本发明涉及一种新型苯胺化合物和含有该化合物的药物组合物。本发明涉及由以下通式代表的化合物： 代表带有取代基的苯、可能带有也可能不带取代基的杂环缩合苯、可能带有也可能不带取代基的吡啶、环己烷或萘的二价残基 或 Ar 代表芳基，可以有取代基，也可以没有取代基； X 代表-NH-、氧原子或硫原子； Y 代表-NR4-、氧原子、硫原子、亚砜或砜； Z 代表单键或-NR5-； R4 代表氢原子、低级烷基、芳基或硅烷化低级烷基，可带有或不带有取代基； R5 代表氢原子、低级烷基、芳基或硅烷化低级烷基，可以有或没有取代基；以及 n 代表 0 至 15 的整数。 本发明化合物以药物组合物的形式使用，特别是作为酰基辅酶 A 胆固醇酰基转移酶（ACAT）抑制剂。
• Novel anilide compounds and drugs containing the same
  申请人：Kowa Company, Ltd.,Japan

  公开号：US20020099074A1

  公开（公告）日：2002-07-25

  The invention relates to a novel anilide compound and a pharmaceutical composition comprising the same. The invention relates to a compound represented by the following general formula: 1 represents a divalent residue of benzene with a substituent(s), heterocycle-condensed benzene which may or may not have a substituent, pyridine which may or may not have a substituent, cyclohexane or naphthalene 2 Ar represents an aryl group which may or may not have a substituent, X represents —NH—, oxygen atom or sulfur atom; Y represents —NR 4 —, oxygen atom, sulfur atom, sulfoxide or sulfone; Z represents single bond or —NR 5 —; R 4 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; R 5 represents hydrogen atom, a lower alkyl group, an aryl group or a silylated lower alkyl group which may or may not have a substituent; and n represents an integer of 0 to 15. The inventive compounds are useful in the form of pharmaceutical composition, specifically as acyl coenzyme A cholesterol acyltransferase (ACAT) inhibitor.

  本发明涉及一种新型苯胺化合物和含有该化合物的药物组合物。本发明涉及一种由以下通式表示的化合物： 1 代表带有取代基的苯、可以带有或不带有取代基的杂环缩合苯、可以带有或不带有取代基的吡啶、环己烷或萘的二价残基 2 Ar 代表芳基，可以有取代基，也可以没有取代基、 X 代表-NH-、氧原子或硫原子； Y 代表-NR 4 -、氧原子、硫原子、亚砜或砜； Z 代表单键或-NR 5 -; R 4 代表氢原子、低级烷基、芳基或硅烷化低级烷基，可带有或不带有取代基； R 5 代表氢原子、低级烷基、芳基或硅烷化低级烷基，可带有或不带有取代基；以及 n 代表 0 至 15 的整数。 本发明化合物以药物组合物的形式使用，特别是作为酰基辅酶 A 胆固醇酰基转移酶（ACAT）抑制剂。
• NOVEL CYCLIC DIAMINE COMPOUNDS AND MEDICINE CONTAINING THE SAME
  申请人：Kowa Co., Ltd.

  公开号：EP0987254B1

  公开（公告）日：2004-12-22